These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 20807186)

  • 1. Conformational diseases: structural studies of aggregation of polyglutamine proteins.
    Papaleo E; Invernizzi G
    Curr Comput Aided Drug Des; 2011 Mar; 7(1):23-43. PubMed ID: 20807186
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Conformational changes and aggregation of expanded polyglutamine proteins as therapeutic targets of the polyglutamine diseases: exposed beta-sheet hypothesis.
    Nagai Y; Popiel HA
    Curr Pharm Des; 2008; 14(30):3267-79. PubMed ID: 19075705
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multi-domain misfolding: understanding the aggregation pathway of polyglutamine proteins.
    Saunders HM; Bottomley SP
    Protein Eng Des Sel; 2009 Aug; 22(8):447-51. PubMed ID: 19589877
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic approaches to polyglutamine diseases: combating protein misfolding and aggregation.
    Herbst M; Wanker EE
    Curr Pharm Des; 2006; 12(20):2543-55. PubMed ID: 16842177
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Molecular therapy targeting protein misfolding and aggregation for the polyglutamine diseases].
    Nagai Y
    Rinsho Shinkeigaku; 2009 Nov; 49(11):913-6. PubMed ID: 20030247
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analyzing the aggregation of polyglutamine-expansion proteins and its modulation by molecular chaperones.
    Kubota H; Kitamura A; Nagata K
    Methods; 2011 Mar; 53(3):267-74. PubMed ID: 21195182
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protein Misfolding and Aggregation as a Therapeutic Target for Polyglutamine Diseases.
    Takeuchi T; Nagai Y
    Brain Sci; 2017 Oct; 7(10):. PubMed ID: 29019918
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Advances in the understanding of protein misfolding and aggregation through molecular dynamics simulation.
    Rahman A; Saikia B; Gogoi CR; Baruah A
    Prog Biophys Mol Biol; 2022 Nov; 175():31-48. PubMed ID: 36044970
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protein Aggregation Inhibitors as Disease-Modifying Therapies for Polyglutamine Diseases.
    Minakawa EN; Nagai Y
    Front Neurosci; 2021; 15():621996. PubMed ID: 33642983
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Monitoring polyglutamine toxicity in yeast.
    Duennwald ML
    Methods; 2011 Mar; 53(3):232-7. PubMed ID: 21144902
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Polyglutamine expansion mutation yields a pathological epitope linked to nucleation of protein aggregate: determinant of Huntington's disease onset.
    Sugaya K; Matsubara S; Kagamihara Y; Kawata A; Hayashi H
    PLoS One; 2007 Jul; 2(7):e635. PubMed ID: 17653262
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular dynamics analysis of the aggregation propensity of polyglutamine segments.
    Wen J; Scoles DR; Facelli JC
    PLoS One; 2017; 12(5):e0178333. PubMed ID: 28542401
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PolyQ fibrillation in the cell nucleus: who's bad?
    von Mikecz A
    Trends Cell Biol; 2009 Dec; 19(12):685-91. PubMed ID: 19796946
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Peptide-based therapeutic approaches for treatment of the polyglutamine diseases.
    Takeuchi T; Popiel HA; Futaki S; Wada K; Nagai Y
    Curr Med Chem; 2014; 21(23):2575-82. PubMed ID: 24533807
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of protein misfolding/aggregation using polyglutamine binding peptide QBP1 as a therapy for the polyglutamine diseases.
    Popiel HA; Takeuchi T; Burke JR; Strittmatter WJ; Toda T; Wada K; Nagai Y
    Neurotherapeutics; 2013 Jul; 10(3):440-6. PubMed ID: 23504628
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Surface plasmon resonance characterization of specific binding of polyglutamine aggregation inhibitors to the expanded polyglutamine stretch.
    Okamoto Y; Nagai Y; Fujikake N; Akiko Popiel H; Yoshioka T; Toda T; Inui T
    Biochem Biophys Res Commun; 2009 Jan; 378(3):634-9. PubMed ID: 19061859
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Study of the aggregation mechanism of polyglutamine peptides using replica exchange molecular dynamics simulations.
    Nakano M; Ebina K; Tanaka S
    J Mol Model; 2013 Apr; 19(4):1627-39. PubMed ID: 23288093
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Polyglutamine expansion diseases: More than simple repeats.
    Silva A; de Almeida AV; Macedo-Ribeiro S
    J Struct Biol; 2018 Feb; 201(2):139-154. PubMed ID: 28928079
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neurotoxic protein oligomerisation associated with polyglutamine diseases.
    Hands SL; Wyttenbach A
    Acta Neuropathol; 2010 Oct; 120(4):419-37. PubMed ID: 20514488
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structure and Dynamics of the Huntingtin Exon-1 N-Terminus: A Solution NMR Perspective.
    Baias M; Smith PE; Shen K; Joachimiak LA; Żerko S; Koźmiński W; Frydman J; Frydman L
    J Am Chem Soc; 2017 Jan; 139(3):1168-1176. PubMed ID: 28085263
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.